Respiratory tract

Data From First-In-Human RheOx™ Bronchial Rheoplasty Trial to be Presented at the European Respiratory Society

Retrieved on: 
Wednesday, August 8, 2018
Respiratory system, Anatomy, Respiration, RTT, Bronchitis, Mucus, Respiratory tract, Lung, Bronchus, Acute bronchitis, Eosinophilic bronchitis

During the session, Professor Arschang Valipour, MD, FCCP, will present initial data from the multicenter, single-armed safety study of the RheOx system in patients with Chronic Bronchitis.

Key Points: 
  • During the session, Professor Arschang Valipour, MD, FCCP, will present initial data from the multicenter, single-armed safety study of the RheOx system in patients with Chronic Bronchitis.
  • The first-in-human study in Chronic Bronchitis was designed to provide initial safety and proof-of-concept data for the Bronchial Rheoplasty procedure which targets the cells responsible for mucus hypersecretion.
  • "We have accomplished what drugs have not by developing a medical device to directly treat the mucus-producing cells in the airways that cause debilitating cough and mucus symptoms.
  • With this data, Gala is at the forefront of the next generation of targeted Interventional Pulmonary technologies, offering clinically meaningful outcomes to patients."

Researchers Identify Distinct Airway and Gastrointestinal Microbiomes in Child Sufferers of Chronic Cough

Retrieved on: 
Wednesday, July 25, 2018
Medicine, Cough, RTT, Health, Chronic lower respiratory diseases, Clinical medicine, Asthma, Respiratory tract, Gastroesophageal reflux disease, Habit cough, Chronic airway-digestive inflammatory disease

The study, published online this month in Pediatric Pulmonology, is the first to assess the bacterial population of the airway and gastrointestinal systems of children with chronic cough using bacterial DNA sequencing.

Key Points: 
  • The study, published online this month in Pediatric Pulmonology, is the first to assess the bacterial population of the airway and gastrointestinal systems of children with chronic cough using bacterial DNA sequencing.
  • Unlike an acute cough, which typically lasts fewer than two weeks and is frequently associated with a respiratory tract infection, chronic cough is often related to an underlying respiratory or gastrointestinal issue such as asthma, upper airway disorders, or gastroesophageal reflux disease (GERD).
  • "This first-of-its-kind study could improve assessment and treatment for children with chronic cough by allowing clinicians to better understand the underlying condition."
  • Researchers also noted that across diagnoses, inflammation of the lower airway was associated with similarity between the lower airway microbiota and the upper airway microbiota.

The airway management devices market is projected to grow at a CAGR of 5.6%

Retrieved on: 
Monday, July 16, 2018
Medicine, Clinical medicine, Health care, Airway management, Medical equipment, Laryngoscopy, Respiratory tract, Advanced airway management

In 2018, the infraglottic devices segment is expected to account for the largest share of the global airway management devices market.

Key Points: 
  • In 2018, the infraglottic devices segment is expected to account for the largest share of the global airway management devices market.
  • On the basis type of airway management devices, the market is segmented into supraglottic airway management devices, infraglottic airway management devices, resuscitators, laryngoscopes, and other airway management devices such as stylets, bronchial blocking tubes, lumen tubes, and suction devices.In 2018, the infraglottic devices segment is expected to account for the largest share of the global airway management devices market.
  • This report provides insights into the following pointers:
    Market Penetration: Comprehensive information on the product portfolios of the top players in the airway management devices market.
  • The report analyzes the markets for various airway management devices across regions
    Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the airway management devices market
    ReportLinker is an award-winning market research solution.

Gala Therapeutics Receives FDA IDE Approval for a US Early Feasibility Study of Its RheOx™ System to Treat Chronic Bronchitis

Retrieved on: 
Thursday, July 12, 2018
Respiratory system, Anatomy, Respiration, Chronic lower respiratory diseases, RTT, Bronchitis, Respiratory tract, Mucus, Chronic obstructive pulmonary disease, Bronchus, Lung, Plastic bronchitis

MENLO PARK, Calif., July 12, 2018 /PRNewswire/ --Gala Therapeutics (Gala) today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct an Early Feasibility Study (EFS) to examine the safety of the RheOx system in subjects with Chronic Bronchitis.

Key Points: 
  • MENLO PARK, Calif., July 12, 2018 /PRNewswire/ --Gala Therapeutics (Gala) today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct an Early Feasibility Study (EFS) to examine the safety of the RheOx system in subjects with Chronic Bronchitis.
  • "Patients with Chronic Bronchitis suffer daily with mucus hypersecretion and cough," stated Jonathan Waldstreicher, MD, Chief Executive Officer of Gala.
  • "We developed the Bronchial Rheoplasty procedure to directly treat the abnormal airway cells responsible for Chronic Bronchitis, which are not impacted by inhaled medications.
  • Gala Therapeutics is the first company to bring an interventional pulmonary procedure targeting Chronic Bronchitis to the United States.